Winchester syndrome (WS) is a part of an inheritable group of disorders called osteolysis syndromes. It is known to primarily affect the hands and feet, before involving the rest of the skeleton, and is carried in an autosomal recessive pattern. Two other disorders share a similar pathological pattern: Torg syndrome and nodulosis arthropathy osteolysis (NAO) syndrome. Because these conditions have several common features, they have been considered to be part of the same clinical spectrum. WS and Torg syndrome is referred as one disease by some, and NAO is regarded as a variant of the same. All aforementioned conditions are mediated by mutations in the matrix metalloproteinase (MMP) 2 gene, which leads to reduced activity of matrix metalloproteinases.

The first signs of the disease appear in infancy, and their distribution is symmetrical [1]. The skeletal system is the most affected, as the main feature of WS is marked lysis of the bones in the hands and feet. In addition, skeletal deformities, as well as osteoporosis in other bones, has been reported [2]. Patients may also display coarse facial features, and suffer from visual disturbances due to corneal opacification [3] [4] [5].

Other non-skeletal findings include contracture formation, subcutaneous nodules (these appear on the hands), hyperpigmentation, skin thickening, lichenification and banding, abnormally excessive body hair growth (hypertrichosis), myocardial damage, and gum hypertrophy [6] [7].

Arthralgia and loss of function of joints in the hands is a documented complaint. Initially, findings may be almost identical to those of rheumatic arthritis.

No specific diagnostic tests are available for Winchester syndrome. Biochemical studies that are requested are carried out in order to exclude metabolic and storage diseases such as mucopolysaccharidosis and mucolipidosis, as well as autoimmune disorders, particularly rheumatoid arthritis [1] [8].

As the primary pathological processes taking place are bone destruction and resorption, radiography is the chief investigation in cases of WS because it allows visualization of varying degrees of bone and joint pathology, which are in direct proportion to the duration of the illness. These appear on film as osteolytic lesions affecting carpal, metacarpal and phalangeal bones (and corresponding bones in the feet), as well as widespread reduced bone density. Further characteristic features include metaphyseal and epiphyseal abnormalities of the long bones and medullary cavity expansion. One of the overall results of the skeletal damage described is ankylosis.

Histological analysis of biopsy samples from skin lesions further consolidates the diagnosis. Basic histological images show elevated melanin and inflammatory cell levels in the deeper layers of the skin. Electron microscopy reveals fibroblast changes in form of abnormal mitochondria and various cell organelles.

There is currently no cure for Winchester Syndrome, and treatment focuses on managing symptoms and improving quality of life. This may involve a multidisciplinary approach, including physical therapy to maintain joint mobility, orthopedic interventions to address bone deformities, and pain management strategies. Regular monitoring by a team of specialists is important to address the evolving needs of the patient.

The prognosis for individuals with Winchester Syndrome varies depending on the severity of symptoms and the effectiveness of management strategies. While the condition is progressive, early intervention and supportive care can help improve function and quality of life. Life expectancy may be reduced in severe cases, but many individuals can lead fulfilling lives with appropriate care.

Winchester Syndrome is caused by mutations in the MMP14 gene, which provides instructions for making an enzyme involved in the breakdown of proteins in the extracellular matrix. This enzyme is crucial for normal bone and connective tissue development. Mutations in this gene disrupt normal enzyme function, leading to the accumulation of substances that cause the symptoms of the syndrome.

Winchester Syndrome is extremely rare, with only a few cases reported in the medical literature. It affects both males and females and has been identified in various ethnic groups. Due to its rarity, the exact prevalence is unknown, and it is likely underdiagnosed.

The pathophysiology of Winchester Syndrome involves the accumulation of glycosaminoglycans (GAGs) in the connective tissues due to impaired breakdown. This accumulation leads to the thickening and stiffening of tissues, resulting in the characteristic joint and bone abnormalities. The exact mechanisms by which MMP14 mutations lead to these changes are still being studied.

As a genetic disorder, there is no known way to prevent Winchester Syndrome. Genetic counseling may be beneficial for families with a history of the condition, as it can provide information about the risks of passing the disorder to offspring and discuss potential reproductive options.

Winchester Syndrome is a rare genetic disorder characterized by progressive joint and bone abnormalities due to mutations in the MMP14 gene. While there is no cure, early diagnosis and a multidisciplinary approach to management can help improve quality of life. Understanding the genetic basis and pathophysiology of the syndrome is crucial for developing future therapeutic strategies.

For patients and families affected by Winchester Syndrome, it is important to work closely with a team of healthcare providers to manage symptoms and maintain quality of life. Regular follow-up appointments, physical therapy, and appropriate interventions can help address the challenges posed by the condition. Genetic counseling can provide valuable information and support for affected families.

1. Prapanpoch S, Jorgenson RJ, Langlais RP, Nummikoski PV. Winchester syndrome. A case report and literature review. Oral Surg Oral Med Oral Pathol. 1992;74(5):671-677.
2. Sidwell RU, Brueton LA, Grabczynska SA, Francis N, Staughton RCD. Progressive multilayered banded skin in Winchester syndrome. J Am Acad Dermatol. 2004;50(2 Suppl): S53-S56.
3. Hall CM. International nosology and classification of constitutional disorders of bone (2001). Am J Med Genet. 2002;113(1):65–77.
4. Zankl A, Bonafe L, Calcaterra V, Di Rocco M, Superti-Furga. A 2005 Winchester syndrome caused by a homozygous mutation affecting the active site of matrix metalloproteinase 2. Clin Genet. 2005;67(3): 261–266.
5. Zankl A, Pachman L, Poznanski A, et al. Torg syndrome is caused by inactivating mutations in MMP2 and is allelic to NAO and Winchester syndrome. J Bone Miner Res. 2007;22(2):329–333.
6. Superti-Furga A, Unger S. Nosology and classification of genetic skeletal disorders: 2006 revision. Am J Med Genet A. 2007;143A(1):1-18.
7. Phadke SR, Ramirez M, Difeo A, Martignetti JA, Girisha KM. Torg-Winchester syndrome: lack of efficacy of pamidronate therapy. Clin Dysmorphol. 2007;16(2):95-100.
8. Nabai H, Mehregan AH, Mortezai A, Alipour P, Karimi FZ. Winchester syndrome: report of a case from Iran. J Cutan Pathol. 1977;4(5):281-285.